Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver

Kota Kato1, Masato Ohbuchi1, Satoko Hamamura1

  • 1Drug Metabolism Research Laboratories, Astellas Pharma Inc., Osaka, Japan (K.K., Ma.O., K.S., N.N., A.K., T.U.); PhoenixBio Co., Ltd., Hiroshima, Japan (S.H., H.O., C.T.); Liver Research Project Center, Hiroshima University, Hiroshima, Japan (C.T.); Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science (Y.K., Mi.O.), Chromosome Engineering Research Center (Y.K., Mi.O.), Tottori University, Tottori, Japan; ADME & Tox Research Institute, Sekisui Medical Co., Ltd., Tokyo, Japan (H.K.).

Insights

We created new chimeric mice lacking mouse CYP3A enzymes to better predict human drug metabolism. This model enhances the accuracy of pharmacokinetic studies by minimizing interference from residual mouse enzymes.

Area of Science:

  • Pharmacology
  • Genetics
  • Biotechnology

Background:

  • Conventional chimeric mice with humanized livers (PXB-mice) can be influenced by residual mouse metabolic enzymes, impacting drug metabolism prediction.
  • Mouse cytochrome P450 3A (CYP3A) enzymes are a major source of metabolic interference in current models.

Purpose of the Study:

  • To develop a novel chimeric mouse model lacking murine CYP3A to improve the prediction of human drug metabolism and pharmacokinetics.
  • To overcome limitations of existing humanized liver mouse models by eliminating endogenous mouse CYP3A activity.

Main Methods:

  • Development of murine CYP3A knockout (KO) chimeric mice transplanted with human hepatocytes.
  • Analysis of human P450s, UGTs, SULTs, and transporter mRNA expression via quantitative real-time-polymerase chain reaction.
  • Assessment of midazolam and triazolam metabolic activities in liver and intestinal microsomes.

Main Results:

  • Humanized livers in CYP3A KO chimeric mice expressed human P450s, UGTs, SULTs, and transporters similarly to PXB-mice.
  • Absence of murine Cyp3a11 mRNA confirmed in the liver and intestine of CYP3A KO chimeric mice.
  • Drug metabolism findings for midazolam and triazolam were comparable in liver microsomes but attenuated in intestinal microsomes compared to PXB-mice.

Conclusions:

  • Murine CYP3A KO chimeric mice provide a valuable model for studying human drug metabolism, reducing interference from endogenous mouse enzymes.
  • Human hepatocyte transplantation in CYP3A KO mice successfully restored human drug-metabolizing enzyme expression, though some murine enzyme upregulation persisted.
  • This model offers improved potential for accurate prediction of drug metabolism and pharmacokinetics in humans.